Studying blood markers in cancer patients on immunotherapy
Part of Cancer clinical trials.
This study looks at tiny particles (microRNA) and cancer cells in the blood of people with cancer who are getting immunotherapy. It aims to find patterns that might help doctors better understand how the treatment is working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 20 years old or older.
- You have been diagnosed with cancer and are receiving immunotherapy.
- You are able to understand and sign a consent form to join the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks for early “predictive clues” (often blood or test markers) that can forecast immune-related side effects in people treated with immune checkpoint medicines. The goal is to help doctors recognize who may be more likely to have these side effects while receiving treatment.
This study checks whether tiny bits of tumor DNA in the blood can be measured over time in people with non-small cell lung cancer who are receiving immunotherapy. It aims to see if these blood tests can help track the cancer response or changes during treatment.
This study looks at blood samples from people with cancer who are starting immunotherapy. Researchers want to find markers that might predict how well the treatment works and whether it could cause side effects.
This study is looking at a specific type of immune cell (called TLR4+ cells) in the blood of people with solid tumors. By studying these cells, researchers hope to learn more about how the immune system reacts to cancer and to treatments.
This study collects blood and tumor samples to understand how well cancer immunotherapy works and what side effects may happen. It mainly helps researchers by checking “immune markers” before treatment starts, while you receive planned immune checkpoint therapy.
This study looks at blood samples from people with blood cancers to find markers that might predict how well immunotherapy will work. The goal is to help doctors choose the right treatment for each person.
Hear when a new MicroRNAs trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.